The DOJ dropped its Pfizer bribery probe in China and Mexico soon after Pam Bondi, a former Pfizer legal consultant, became Attorney General in February 2025. The investigation’s closure, evident from Pfizer’s latest filings, has raised concerns about Bondi’s influence and DOJ impartiality.
For the past several years, pharmaceutical giant Pfizer has been under investigation by the U.S. Department of Justice for potential foreign corruption violations related to its activities in China and Mexico, according to the company’s financial filings.
But that appears to have changed after the Trump administration tapped Pam Bondi — previously an outside legal counsel for Pfizer — to lead the Justice department as attorney general.
In the company’s most recent annual report, filed three weeks after Bondi took office in early February, there was no longer any reference to the Justice Department investigations into the company’s potential violation of the Foreign Corrupt Practice Act. A quarterly a report in May also contains no reference to these investigations.
Hellbound and Down 